Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.54 | -10.0934579439 | 5.35 | 5.5384 | 4.66 | 18481 | 5.14691441 | CS |
4 | -1.04 | -17.7777777778 | 5.85 | 6.19 | 4.66 | 19643 | 5.50465985 | CS |
12 | -6.79 | -58.5344827586 | 11.6 | 12.4 | 4.66 | 25720 | 7.28094033 | CS |
26 | -7.4725 | -60.838591492 | 12.2825 | 16.0675 | 4.66 | 129892 | 12.23153519 | CS |
52 | -10.69 | -68.9677419355 | 15.5 | 23.5 | 4.66 | 203408 | 15.53164965 | CS |
156 | -62.44 | -92.8475836431 | 67.25 | 92.5 | 4.66 | 184869 | 27.98240297 | CS |
260 | -389.44 | -98.7799619531 | 394.25 | 449.75 | 4.66 | 226923 | 75.52919736 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관